APHD-012

DRUG3 trials

Sponsors

Aphaia Pharma US LLC

Conditions

Glucose Tolerance ImpairedObeseObese Patients (BMI ≥ 30 kg/m²)Obese With ComorbiditiesPreDiabetes

Phase 2

A Study of Distal Jejunal-release Dextrose in Obese Participants

Active, not recruitingNCT05385978

Aphaia Pharma US LLCObese

Start: 2022-11-01End: 2024-11-11Target: 150Updated: 2024-10-16

A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation in Subjects With a Pathological Oral Glucose Tolerance Test

CompletedNCT05803772

Aphaia Pharma US LLCGlucose Tolerance Impaired, PreDiabetes

Start: 2023-03-31End: 2024-02-12Updated: 2024-10-16

A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities

RecruitingNCT07008456

Aphaia Pharma US LLCObese Patients (BMI ≥ 30 kg/m²), Obese With Comorbidities

Start: 2025-09-12End: 2026-07-31Target: 102Updated: 2025-09-16

Related Papers

Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials

Diabetes Obesity and Metabolism2025-09-17